Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2

Zoe Fox; Francisco Antunes; Rick Davey; Brian Gazzard; Nancy Klimas; Ann Labriola; Marcelo Losso; James D Neaton; Andrew N Phillips; Kiat Ruxrungtham; Schlomo Staszewski; Laurence Weiss; Jens D Lundgren; ESPRIT Research Group

doi:10.1111/j.1468-1293.2007.00440.x

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2

Zoe Fox, Francisco Antunes, Rick Davey, Brian Gazzard, Nancy Klimas, Ann Labriola, Marcelo Losso, James D Neaton, Andrew N Phillips, Kiat Ruxrungtham, Schlomo Staszewski, Laurence Weiss, Jens D Lundgren, ESPRIT Research Group

7 Citationer (Scopus)

Abstract

BACKGROUND: ESPRIT is a randomized trial comparing the clinical impact of interleukin (IL)-2 plus antiretrovirals vs antiretrovirals alone. Identification of factors that influence the relationship between IL-2 and CD4 count recovery will enable better personalization of treatment with IL-2 in HIV-1-positive individuals. The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks). METHODS: We included patients initiating IL-2 at the 7.5 MIU dose with an 8-month CD4 count, measured at least 30 days after their last cycle. We identified baseline predictors of CD4 count changes over 8 months using linear regression. RESULTS: Of 2090 patients assigned IL-2, 1673 (80%) were included in the analysis. The median (interquartile range) baseline CD4 count was 461 (370, 587) cells/microL with a median increase of 233 (90, 411) cells/microL at month 8. After adjustments, significant predictors of CD4 count change included CD4 nadir (29.8 cells/microL greater increase per 100 cells/microL higher; P<0.0001), last CD4 count before baseline (mean 36.0 cells/microL greater increase per 100 cells/microL higher; P<0.0001), time from antiretroviral start to baseline (8.3 cells/microL smaller increase per year longer; P=0.001), age (11.7 cells/microL smaller increase per 5 years older; P=0.005) and race (79.7 cells/microL greater increase for black patients vs white patients; P=0.003). A linear relationship existed between total IL-2 dose in the first cycle and CD4 count change (73.1 cells/microL greater increase per 15 MIU higher; P<0.0001). CONCLUSIONS: Prior nadir and current CD4 counts, age and IL-2 dose are major determinants of CD4 increases induced by with intermittent administration of IL-2 in HIV-1-positive individuals on antiretrovirals. The clinical function of these induced CD4 cells is under study.

Originalsprog	Engelsk
Tidsskrift	HIV Medicine
Vol/bind	8
Udgave nummer	2
Sider (fra-til)	112-23
Antal sider	12
ISSN	1464-2662
DOI	https://doi.org/10.1111/j.1468-1293.2007.00440.x
Status	Udgivet - 2007

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1111/j.1468-1293.2007.00440.x

http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17352768&query_hl=1&itool=pubmed_docsum

Citationsformater

Fox, Z., Antunes, F., Davey, R., Gazzard, B., Klimas, N., Labriola, A., Losso, M., Neaton, J. D., Phillips, A. N., Ruxrungtham, K., Staszewski, S., Weiss, L., Lundgren, J. D., & ESPRIT Research Group (2007). Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2. HIV Medicine, 8(2), 112-23. https://doi.org/10.1111/j.1468-1293.2007.00440.x

Fox, Z, Antunes, F, Davey, R, Gazzard, B, Klimas, N, Labriola, A, Losso, M, Neaton, JD, Phillips, AN, Ruxrungtham, K, Staszewski, S, Weiss, L, Lundgren, JD & ESPRIT Research Group 2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, bind 8, nr. 2, s. 112-23. https://doi.org/10.1111/j.1468-1293.2007.00440.x

@article{491250671e314f7587e904d0f909b8a6,

title = "Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2",

abstract = "BACKGROUND: ESPRIT is a randomized trial comparing the clinical impact of interleukin (IL)-2 plus antiretrovirals vs antiretrovirals alone. Identification of factors that influence the relationship between IL-2 and CD4 count recovery will enable better personalization of treatment with IL-2 in HIV-1-positive individuals. The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks). METHODS: We included patients initiating IL-2 at the 7.5 MIU dose with an 8-month CD4 count, measured at least 30 days after their last cycle. We identified baseline predictors of CD4 count changes over 8 months using linear regression. RESULTS: Of 2090 patients assigned IL-2, 1673 (80%) were included in the analysis. The median (interquartile range) baseline CD4 count was 461 (370, 587) cells/microL with a median increase of 233 (90, 411) cells/microL at month 8. After adjustments, significant predictors of CD4 count change included CD4 nadir (29.8 cells/microL greater increase per 100 cells/microL higher; P<0.0001), last CD4 count before baseline (mean 36.0 cells/microL greater increase per 100 cells/microL higher; P<0.0001), time from antiretroviral start to baseline (8.3 cells/microL smaller increase per year longer; P=0.001), age (11.7 cells/microL smaller increase per 5 years older; P=0.005) and race (79.7 cells/microL greater increase for black patients vs white patients; P=0.003). A linear relationship existed between total IL-2 dose in the first cycle and CD4 count change (73.1 cells/microL greater increase per 15 MIU higher; P<0.0001). CONCLUSIONS: Prior nadir and current CD4 counts, age and IL-2 dose are major determinants of CD4 increases induced by with intermittent administration of IL-2 in HIV-1-positive individuals on antiretrovirals. The clinical function of these induced CD4 cells is under study.",

keywords = "Adult, CD4 Lymphocyte Count, Drug Administration Schedule, Drug Therapy, Combination, Female, HIV Infections, HIV Protease Inhibitors, HIV-1, Humans, Interleukin-2, Male, Patient Compliance, RNA, Viral, Recombinant Proteins, Reverse Transcriptase Inhibitors",

author = "Zoe Fox and Francisco Antunes and Rick Davey and Brian Gazzard and Nancy Klimas and Ann Labriola and Marcelo Losso and Neaton, {James D} and Phillips, {Andrew N} and Kiat Ruxrungtham and Schlomo Staszewski and Laurence Weiss and Lundgren, {Jens D} and {ESPRIT Research Group}",

year = "2007",

doi = "10.1111/j.1468-1293.2007.00440.x",

language = "English",

volume = "8",

pages = "112--23",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2

AU - Fox, Zoe

AU - Antunes, Francisco

AU - Davey, Rick

AU - Gazzard, Brian

AU - Klimas, Nancy

AU - Labriola, Ann

AU - Losso, Marcelo

AU - Neaton, James D

AU - Phillips, Andrew N

AU - Ruxrungtham, Kiat

AU - Staszewski, Schlomo

AU - Weiss, Laurence

AU - Lundgren, Jens D

AU - ESPRIT Research Group

PY - 2007

Y1 - 2007

N2 - BACKGROUND: ESPRIT is a randomized trial comparing the clinical impact of interleukin (IL)-2 plus antiretrovirals vs antiretrovirals alone. Identification of factors that influence the relationship between IL-2 and CD4 count recovery will enable better personalization of treatment with IL-2 in HIV-1-positive individuals. The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks). METHODS: We included patients initiating IL-2 at the 7.5 MIU dose with an 8-month CD4 count, measured at least 30 days after their last cycle. We identified baseline predictors of CD4 count changes over 8 months using linear regression. RESULTS: Of 2090 patients assigned IL-2, 1673 (80%) were included in the analysis. The median (interquartile range) baseline CD4 count was 461 (370, 587) cells/microL with a median increase of 233 (90, 411) cells/microL at month 8. After adjustments, significant predictors of CD4 count change included CD4 nadir (29.8 cells/microL greater increase per 100 cells/microL higher; P<0.0001), last CD4 count before baseline (mean 36.0 cells/microL greater increase per 100 cells/microL higher; P<0.0001), time from antiretroviral start to baseline (8.3 cells/microL smaller increase per year longer; P=0.001), age (11.7 cells/microL smaller increase per 5 years older; P=0.005) and race (79.7 cells/microL greater increase for black patients vs white patients; P=0.003). A linear relationship existed between total IL-2 dose in the first cycle and CD4 count change (73.1 cells/microL greater increase per 15 MIU higher; P<0.0001). CONCLUSIONS: Prior nadir and current CD4 counts, age and IL-2 dose are major determinants of CD4 increases induced by with intermittent administration of IL-2 in HIV-1-positive individuals on antiretrovirals. The clinical function of these induced CD4 cells is under study.

AB - BACKGROUND: ESPRIT is a randomized trial comparing the clinical impact of interleukin (IL)-2 plus antiretrovirals vs antiretrovirals alone. Identification of factors that influence the relationship between IL-2 and CD4 count recovery will enable better personalization of treatment with IL-2 in HIV-1-positive individuals. The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks). METHODS: We included patients initiating IL-2 at the 7.5 MIU dose with an 8-month CD4 count, measured at least 30 days after their last cycle. We identified baseline predictors of CD4 count changes over 8 months using linear regression. RESULTS: Of 2090 patients assigned IL-2, 1673 (80%) were included in the analysis. The median (interquartile range) baseline CD4 count was 461 (370, 587) cells/microL with a median increase of 233 (90, 411) cells/microL at month 8. After adjustments, significant predictors of CD4 count change included CD4 nadir (29.8 cells/microL greater increase per 100 cells/microL higher; P<0.0001), last CD4 count before baseline (mean 36.0 cells/microL greater increase per 100 cells/microL higher; P<0.0001), time from antiretroviral start to baseline (8.3 cells/microL smaller increase per year longer; P=0.001), age (11.7 cells/microL smaller increase per 5 years older; P=0.005) and race (79.7 cells/microL greater increase for black patients vs white patients; P=0.003). A linear relationship existed between total IL-2 dose in the first cycle and CD4 count change (73.1 cells/microL greater increase per 15 MIU higher; P<0.0001). CONCLUSIONS: Prior nadir and current CD4 counts, age and IL-2 dose are major determinants of CD4 increases induced by with intermittent administration of IL-2 in HIV-1-positive individuals on antiretrovirals. The clinical function of these induced CD4 cells is under study.

KW - Adult

KW - CD4 Lymphocyte Count

KW - Drug Administration Schedule

KW - Drug Therapy, Combination

KW - Female

KW - HIV Infections

KW - HIV Protease Inhibitors

KW - HIV-1

KW - Humans

KW - Interleukin-2

KW - Male

KW - Patient Compliance

KW - RNA, Viral

KW - Recombinant Proteins

KW - Reverse Transcriptase Inhibitors

U2 - 10.1111/j.1468-1293.2007.00440.x

DO - 10.1111/j.1468-1293.2007.00440.x

M3 - Journal article

C2 - 17352768

SN - 1464-2662

VL - 8

SP - 112

EP - 123

JO - HIV Medicine

JF - HIV Medicine

IS - 2

ER -

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater